Findings

What do systematic reviews say?

9 questions · 9 findings · 4 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 22.2%Moderate 4 · 44.4%High 3 · 33.3%

Beta‐blockers vs placebo, no treatment or surveillance only

All‐cause mortality · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in all‐cause mortality compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 0.24 [0.01, 4.75]
1 study · 70 participants
Low

Beta‐blockers vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Beta‐blockers showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.82 [0.67, 1]
4 studies · 1105 participants
Low

Beta‐blockers vs placebo or no intervention

All‐cause mortality maximum · patients with suspected or diagnosed myocardial infarction

Beta‐blockers probably leads to lower all‐cause mortality at maximum compared with placebo or no intervention (moderate certainty).

1 finding from 1 review

Beta‐blockers for suspected or diagnosed acute myocardial infarction 2019 · Cochrane Headline outcomes only
RR 0.93 [0.86, 0.99]
21 studies · 25210 participants
Moderate

Beta‐blockers vs placebo or no intervention

All‐cause mortality at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction

Beta‐blockers showed no clear difference in all‐cause mortality at 'less than 3 months' compared with placebo or no intervention (high certainty).

1 finding from 1 review

Beta‐blockers for suspected or diagnosed acute myocardial infarction 2019 · Cochrane Headline outcomes only
RR 0.94 [0.9, 1]
46 studies · 80452 participants
High

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

All‐cause mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.06]
5 studies · 4207 participants
Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 1.04 [0.75, 1.45]
5 studies · 1187 participants
Moderate

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.11]
4 studies · 7964 participants
High

Intervention not reported

All‐cause mortality at maximum · patients without heart failure

The intervention probably leads to lower all‐cause mortality at maximum (moderate certainty).

1 finding from 1 review

Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
RR 0.81 [0.73, 0.9]
21 studies · 22085 participants
Moderate

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.97
3 studies · 7663 participants
High